XML 34 R24.htm IDEA: XBRL DOCUMENT v3.25.1
Revenue (Tables)
 3 Months Ended
Mar. 31, 2025
Revenue from Contract with Customer [Abstract]  
Schedule of Disaggregation of Revenue
The following table summarizes our revenue recognized in our consolidated condensed statements of operations:
Three Months Ended March 31,
 20252024
Net product revenue$11,601.2 $7,796.5 
Collaboration and other revenue
1,127.3 971.5 
Revenue$12,728.5 $8,768.0 
The following table summarizes revenue, including net product revenue and collaboration and other revenue, by product:
Three Months Ended March 31,
 20252024
U.S.
Outside U.S.Total
U.S.
Outside U.S.Total
Cardiometabolic Health:
Mounjaro$2,655.9 $1,185.9 $3,841.8 $1,520.4 $286.2 $1,806.5 
Zepbound2,305.4 6.5 2,311.9 517.4 — 517.4 
Trulicity770.5 324.7 1,095.2 1,081.9 374.4 1,456.3 
Jardiance(1)
309.8 704.6 1,014.4 368.2 318.3 686.5 
Other cardiometabolic health535.1 409.7 944.8 602.1 424.1 1,026.3 
Total cardiometabolic health6,576.7 2,631.4 9,208.1 4,090.0 1,403.0 5,493.0 
Oncology:
Verzenio657.6 501.3 1,158.9 638.2 412.1 1,050.3 
Other oncology388.2 400.4 788.6 360.1 399.6 759.7 
Total oncology1,045.8 901.7 1,947.5 998.3 811.7 1,810.0 
Immunology:
Taltz476.5 285.4 761.9 347.1 257.0 604.1 
Other immunology101.6 224.6 326.1 50.1 179.8 229.9 
Total immunology578.1 510.0 1,088.0 397.2 436.8 834.0 
Neuroscience189.3 82.8 272.1 163.2 225.9 389.1 
Other99.5 113.3 212.9 45.7 196.2 241.9 
Revenue$8,489.4 $4,239.1 $12,728.5 $5,694.4 $3,073.7 $8,768.0 
(1) Jardiance revenue includes Glyxambi, Synjardy, and Trijardy XR.

The following table summarizes revenue by geographical area:
Three Months Ended March 31,
20252024
Revenue(1):
U.S.$8,489.4 $5,694.4 
Europe2,388.7 1,440.7 
China450.8 376.2 
Japan402.2 363.9 
Rest of world997.4 892.9 
Revenue$12,728.5 $8,768.0 
(1) Revenue is attributed to the countries based on the location of the customer or other party.